GMAB
Genmab
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Beats Expectation
Bearish Abandoned Baby
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GMAB
Genmab A/S
An international biotechnology company focused on creating and developing innovative antibody therapeutics
Pharmaceutical
06/11/1998
07/18/2019
NASDAQ Stock Exchange
2682
12-31
Depository Receipts (Ordinary Shares)
Carl Jacobsens Vej 30, 2500 Valby, Denmark
--
Genmab A/S was incorporated on June 11, 1998. They are an international biotechnology company specializing in the treatment of antibodies for cancer and other diseases. Their core purpose is to improve the lives of patients by creating and developing innovative antibody products. The company's vision is to transform cancer treatments and advance its well-differentiated and well-tolerated antibody pipeline by launching its own patented product in 2025. They are building and expanding their late-stage development and commercial capabilities so that they can bring their proprietary products to market in the future.
Company Financials
EPS
GMAB has released its 2023 Q4 earnings. EPS was reported at 0.36, versus the expected 4.02, missing expectations. The chart below visualizes how GMAB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
GMAB has released its 2024 Q4 earnings report, with revenue of 894.01M, reflecting a YoY change of 26.59%, and net profit of 533.69M, showing a YoY change of 411.58%. The Sankey diagram below clearly presents GMAB’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
